Regenxbio said it plans to submit its Duchenne gene therapy for FDA approval, a move that comes just one month after the company disclosed that regulators wanted to see another clinical trial. The decision signals a potential shift in the regulatory landscape under the current FDA leadership, though the company has not provided detailed evidence that its data package satisfies previous concerns.
The submission represents a high-stakes wager on the agency's evolving stance toward gene therapies for rare diseases. Duchenne muscular dystrophy, a fatal genetic disorder affecting mostly boys, has been a target for several biotech companies, though past approvals have been controversial due to mixed efficacy data.
Regenxbio has not disclosed exactly what new data it will include in the application. The company previously said the FDA requested additional trial results, but it now appears willing to proceed without completing that new study — a gamble that could pay off if regulators are open to flexible evidence standards.
If approved, the therapy would compete with existing treatments and could open a significant new revenue stream for Regenxbio. However, the decision also carries risk: a rejection or request for more trials could damage investor confidence and delay access for patients.
The FDA has not commented on the submission plan. Some analysts caution that the agency may still require more rigorous efficacy data, potentially setting up a contentious review.